<p>Opus Genetics, Inc.（納斯達克：IRD - 獲取免費報告）首席運營官 Joseph Schachle 於 4 月 23 日星期四出售了該公司 4,697 股股票。股票的平均售價為 5.22 美元，總價值為 24,518.34 美元。出售完成後，首席運營官直接持有該公司 296,084 股股票，估值約為 1,545,558.48 美元。此次交易使其持股比例減少了 1.56%。該出售在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站訪問。此次出售是為了覆蓋與股權獎勵歸屬相關的税收扣繳義務。</p>
<p>獲取 <strong>Opus Genetics</strong> 的提醒：</p>
<h2>Opus Genetics 股票下跌 2.1%</h2>
<ul>
<li>未來十年可能飆升的 5 只太空股票</li>
</ul>
<p>在週一的交易中，納斯達克 IRD 的股票下跌了 0.11 美元，達到 5.12 美元。該公司的交易量為 736,774 股，而其平均交易量為 885,269 股。Opus Genetics, Inc.的 12 個月低點為 0.81 美元，12 個月高點為 5.81 美元。該股票的市值為 3.6557 億美元，市盈率為-6.24，貝塔值為 0.52。該公司的 50 日移動平均線為 4.67 美元，200 日移動平均線為 3.07 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>多家研究公司最近對 IRD 發表了評論。Oppenheimer 在 3 月 16 日的研究報告中開始覆蓋 Opus Genetics。他們對該股票給予了 “跑贏大盤” 的評級，並設定了 10.00 美元的目標價。Weiss Ratings 在 4 月 21 日的研究報告中重新發布了對 Opus Genetics 的 “賣出（d-）” 評級。Craig Hallum 在 3 月 11 日的研究報告中對 Opus Genetics 設定了 9.00 美元的目標價，並給予該股票 “買入” 評級。Lifesci Capital 在 2 月 12 日的研究報告中將 Opus Genetics 的評級提升至 “強力買入”。最後，Wall Street Zen 在 3 月 1 日的報告中將 Opus Genetics 的評級從 “賣出” 提升至 “持有”。一位投資分析師對該股票給予了強力買入評級，九位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 10.11 美元。</p>
<ul>
<li>信號提升：推動行業增長的 2 只關鍵衞星股票</li>
</ul>
<p><strong>獲取我們關於 IRD 的最新研究報告</strong></p>
<h2>機構資金流入和流出</h2>
<p>對該公司的對沖基金和其他機構投資者最近調整了他們的持股。Occudo Quantitative Strategies LP 在第四季度購買了價值 25,000 美元的 Opus Genetics 新頭寸。Comerica Bank 在第一季度購買了價值 29,000 美元的 Opus Genetics 新頭寸。Virtu Financial LLC 在第四季度購買了價值 34,000 美元的 Opus Genetics 新頭寸。Raymond James Financial Inc.在第三季度將其在 Opus Genetics 的持股提高了 95.6%。Raymond James Financial Inc.現在擁有 22,508 股該公司的股票，價值 37,000 美元，此前在上個季度購買了額外的 11,000 股。最後，Johnson Investment Counsel Inc.在第四季度購買了價值 40,000 美元的 Opus Genetics 新頭寸。14.97% 的股票由機構投資者持有。</p>
<h2>關於 Opus Genetics</h2>
<p>（獲取免費報告）</p>
<ul>
<li>這 3 只股票能否因三位數的收益增長而飆升？</li>
</ul>
<p>Opus Genetics Inc 是一家臨牀階段的眼科生物製藥公司，專注於開發和商業化治療屈光和視網膜眼病患者未滿足需求的療法。Opus Genetics Inc，前身為 Ocuphire Pharma Inc，總部位於密歇根州法明頓山。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Opus Genetics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJE?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJE"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Opus Genetics 嗎？</h2>
<p>在你考慮 Opus Genetics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Opus Genetics 並不在名單上。</p>
<p>雖然 Opus Genetics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

<p>Opus Genetics 首席運營官 Joseph Schachle 於 4 月 23 日以平均價格 5.22 美元出售了 4,697 股公司股票，交易總額為 24,518.34 美元。出售後，他持有 296,084 股，估值約為 155 萬美元，反映出其持股比例下降了 1.56%。此次出售是為了支付與股權獎勵相關的税務義務。該股票目前交易價格為 5.12 美元，下跌 2.1%，市值為 3.6557 億美元。分析師的評級意見不一，普遍目標價為 10.11 美元</p>

<p>Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) COO Joseph Schachle sold 4,697 shares of the company's stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $5.22, for a total value of $24,518.34. Following the completion of the sale, the chief operating officer directly owned 296,084 shares in the company, valued at approximately $1,545,558.48. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.</p>
<div class="lb-trans"><p>Opus Genetics, Inc.（納斯達克：IRD - 獲取免費報告）首席運營官 Joseph Schachle 於 4 月 23 日星期四出售了該公司 4,697 股股票。股票的平均售價為 5.22 美元，總價值為 24,518.34 美元。出售完成後，首席運營官直接持有該公司 296,084 股股票，估值約為 1,545,558.48 美元。此次交易使其持股比例減少了 1.56%。該出售在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站訪問。此次出售是為了覆蓋與股權獎勵歸屬相關的税收扣繳義務。</p>
</div><p>Get <strong>Opus Genetics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Opus Genetics</strong> 的提醒：</p>
</div><h2>Opus Genetics Stock Down 2.1%</h2>
<div class="lb-trans"><h2>Opus Genetics 股票下跌 2.1%</h2>
</div><ul>
<li>5 Space Stocks That Could Soar in the Next Decade</li>
</ul>
<div class="lb-trans"><ul>
<li>未來十年可能飆升的 5 只太空股票</li>
</ul>
</div><p>Shares of NASDAQ IRD traded down $0.11 during trading on Monday, reaching $5.12. The company had a trading volume of 736,774 shares, compared to its average volume of 885,269. Opus Genetics, Inc. has a 12-month low of $0.81 and a 12-month high of $5.81. The stock has a market cap of $365.57 million, a PE ratio of -6.24 and a beta of 0.52. The business's 50-day moving average is $4.67 and its 200 day moving average is $3.07.</p>
<div class="lb-trans"><p>在週一的交易中，納斯達克 IRD 的股票下跌了 0.11 美元，達到 5.12 美元。該公司的交易量為 736,774 股，而其平均交易量為 885,269 股。Opus Genetics, Inc.的 12 個月低點為 0.81 美元，12 個月高點為 5.81 美元。該股票的市值為 3.6557 億美元，市盈率為-6.24，貝塔值為 0.52。該公司的 50 日移動平均線為 4.67 美元，200 日移動平均線為 3.07 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of research firms have recently commented on IRD. Oppenheimer began coverage on Opus Genetics in a research note on Monday, March 16th. They issued an &#34;outperform&#34; rating and a $10.00 target price on the stock. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Opus Genetics in a research note on Tuesday, April 21st. Craig Hallum set a $9.00 target price on Opus Genetics and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, March 11th. Lifesci Capital raised Opus Genetics to a &#34;strong-buy&#34; rating in a research note on Thursday, February 12th. Finally, Wall Street Zen raised Opus Genetics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, March 1st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $10.11.</p>
<div class="lb-trans"><p>多家研究公司最近對 IRD 發表了評論。Oppenheimer 在 3 月 16 日的研究報告中開始覆蓋 Opus Genetics。他們對該股票給予了 “跑贏大盤” 的評級，並設定了 10.00 美元的目標價。Weiss Ratings 在 4 月 21 日的研究報告中重新發布了對 Opus Genetics 的 “賣出（d-）” 評級。Craig Hallum 在 3 月 11 日的研究報告中對 Opus Genetics 設定了 9.00 美元的目標價，並給予該股票 “買入” 評級。Lifesci Capital 在 2 月 12 日的研究報告中將 Opus Genetics 的評級提升至 “強力買入”。最後，Wall Street Zen 在 3 月 1 日的報告中將 Opus Genetics 的評級從 “賣出” 提升至 “持有”。一位投資分析師對該股票給予了強力買入評級，九位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 10.11 美元。</p>
</div><ul>
<li>Signal Boost: 2 Key Satellite Stocks Driving Industry Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>信號提升：推動行業增長的 2 只關鍵衞星股票</li>
</ul>
</div><p><strong>Get Our Latest Research Report on IRD</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 IRD 的最新研究報告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the business. Occudo Quantitative Strategies LP bought a new position in shares of Opus Genetics during the fourth quarter valued at $25,000. Comerica Bank bought a new position in shares of Opus Genetics during the first quarter valued at $29,000. Virtu Financial LLC bought a new position in shares of Opus Genetics during the fourth quarter valued at $34,000. Raymond James Financial Inc. lifted its holdings in shares of Opus Genetics by 95.6% during the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company's stock valued at $37,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Johnson Investment Counsel Inc. bought a new position in shares of Opus Genetics during the fourth quarter valued at $40,000. 14.97% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>對該公司的對沖基金和其他機構投資者最近調整了他們的持股。Occudo Quantitative Strategies LP 在第四季度購買了價值 25,000 美元的 Opus Genetics 新頭寸。Comerica Bank 在第一季度購買了價值 29,000 美元的 Opus Genetics 新頭寸。Virtu Financial LLC 在第四季度購買了價值 34,000 美元的 Opus Genetics 新頭寸。Raymond James Financial Inc.在第三季度將其在 Opus Genetics 的持股提高了 95.6%。Raymond James Financial Inc.現在擁有 22,508 股該公司的股票，價值 37,000 美元，此前在上個季度購買了額外的 11,000 股。最後，Johnson Investment Counsel Inc.在第四季度購買了價值 40,000 美元的 Opus Genetics 新頭寸。14.97% 的股票由機構投資者持有。</p>
</div><h2>About Opus Genetics</h2>
<div class="lb-trans"><h2>關於 Opus Genetics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><ul>
<li>Can These 3 Stocks Soar On Triple-Digit Earnings Increases?</li>
</ul>
<div class="lb-trans"><ul>
<li>這 3 只股票能否因三位數的收益增長而飆升？</li>
</ul>
</div><p>Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.</p>
<div class="lb-trans"><p>Opus Genetics Inc 是一家臨牀階段的眼科生物製藥公司，專注於開發和商業化治療屈光和視網膜眼病患者未滿足需求的療法。Opus Genetics Inc，前身為 Ocuphire Pharma Inc，總部位於密歇根州法明頓山。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Opus Genetics</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Opus Genetics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJE" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=IRD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Opus Genetics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Opus Genetics 嗎？</h2>
</div><p>Before you consider Opus Genetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Opus Genetics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opus Genetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Opus Genetics 並不在名單上。</p>
</div><p>While Opus Genetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Opus Genetics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Opus Genetics (NASDAQ:IRD) COO Sells $24,518.34 in Stock

Market Beat

Opus Genetics

醫藥突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

標普生物技術 3 倍做空 - Direxion

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 3 倍做多 - Direxion

2 倍做多納斯達克生物技術 ETF - ProShares

Invesco Nasdaq Biotechnology ETF

動態生物技術與基因組 ETF - Invesco

Opus Genetics（NASDAQ 代碼：IRD）的首席運營官出售了價值 24,518.34 美元的股票